| All patients (n = 792) | Hypertension (n = 540) | No hypertension (n = 252) | p value |
---|---|---|---|---|
Age, years | 62 [51–71] | 66 [55–73] | 54 [48–63] | <0.001 |
Male sex, n (%) | 600 (76) | 389 (72) | 211 (84) | <0.001 |
Body mass index, kg/m2 | 27 [25–30] | 28 [25–31] | 26 [24–29] | <0.001 |
Cardiovascular risk factors | ||||
 Current smoking, n (%) | 339/724 (43) | 194/482 (36) | 145/242 (58) | <0.001 |
 Diabetes mellitus, n (%) | 160/789 (20) | 142/539 (26) | 18/250 (7) | <0.001 |
 Hypercholesterolemia, n (%) | 303/784 (38) | 250/536 (46) | 53/250 (21) | <0.001 |
 Family history for CAD, n (%) | 268/611 (34) | 177/407 (33) | 91/204 (36) | 0.79 |
Systolic blood pressure, mmHg | 130 [117–147] | 135 [119–150] | 126 [114–140] | <0.001 |
Diastolic blood pressure, mmHg | 80 [70–88] | 80 [70–90] | 80 [70–85] | 0.07 |
Heart rate, beats/min | 76 [67–87] | 76 [68–88] | 76 [65–85] | 0.23 |
Time from symptom onset to PCI hospital admission, min | 180 [109–310] | 183 [110–311] | 166 [104–306] | 0.23 |
Door-to-balloon time, min | 30 [22–42] | 30 [23–42] | 29 [20–42] | 0.56 |
Previous infarction, n (%) | 48/791 (6) | 42/539 (8) | 6/631 (2) | <0.01 |
Previous PPCI, n (%) | 67 (9) | 61 (11) | 6 (2) | <0.001 |
Previous CABG, n (%) | 11 (1) | 11 (2) | 0 (0) | 0.02 |
Anterior infarction, n (%) | 395/755 (50) | 262/516 (49) | 133/239 (53) | 0.21 |
Killip-class on admission | Â | Â | Â | 0.52 |
 1, n (%) | 696 (88) | 472 (87) | 224 (89) |  |
 2, n (%) | 59 (7) | 42 (8) | 17 (7) |  |
 3, n (%) | 20 (3) | 16 (3) | 4 (2) |  |
 4, n (%) | 17 (2) | 10 (2) | 7 (3) |  |
Number of diseased vessels | Â | Â | Â | <0.01 |
 1, n (%) | 419 (53) | 261 (48) | 158 (63) |  |
 2, n (%) | 225 (28) | 165 (31) | 60 (24) |  |
 3, n (%) | 148 (19) | 114 (21) | 34 (14) |  |
Infarct related artery | Â | Â | Â | 0.59 |
 Left anterior descending, n (%) | 344 (43) | 240 (44) | 104 (41) |  |
 Right coronary artery, n (%) | 344 (43) | 226 (42) | 118 (47) |  |
 Left circumflex, n (%) | 97 (12) | 68 (13) | 29 (12) |  |
 Left main, n (%) | 5 (1) | 4 (1) | 1 (0) |  |
 Bypass graft, n (%) | 2 (0) | 2 (0) | 0 (0) |  |
TIMI risk score | 3 [2–5] | 4 [2–5] | 2 [2–4] | <0.001 |
TIMI-flow before PPCI | Â | Â | Â | 0.64 |
 TIMI-flow 0, n (%) | 444 (56) | 298 (55) | 146 (58) |  |
 TIMI-flow 1, n (%) | 103 (13) | 73 (14) | 30 (12) |  |
 TIMI-flow 2, n (%) | 128 (16) | 92 (17) | 36 (14) |  |
 TIMI-flow 3, n (%) | 117 (15) | 77 (14) | 40 (16) |  |
TIMI-flow after PPCI | Â | Â | Â | 0.38 |
 TIMI-flow 0, n (%) | 12 (2) | 9 (2) | 3 (1) |  |
 TIMI-flow 1, n (%) | 19 (2) | 14 (3) | 5 (2) |  |
 TIMI-flow 2, n (%) | 61 (8) | 47 (9) | 14 (6) |  |
 TIMI-flow 3, n (%) | 699 (88) | 469 (87) | 230 (91) |  |
Stent implanted, n (%) | 774 (98) | 527 (98) | 247 (98) | 0.60 |
Thrombectomy, n (%) | 190 (24) | 124 (23) | 66 (26) | 0.32 |
Concomitant medications | ||||
 Aspirin, n (%) | 790 (100) | 538 (100) | 252 (100) | 1.0 |
 ß-blockers, n (%) | 757 (96) | 519 (96) | 238 (94) | 0.19 |
 ACE-I/ARB, n (%) | 751 (95) | 515 (95) | 236 (94) | 0.21 |
 Statin, n (%) | 749 (95) | 508 (94) | 241 (96) | 0.47 |
 Aldosterone antagonist, n (%) | 80 (10) | 55 (12) | 25 (10) | 0.34 |